Brought to you by 
AI drug development start-up BioXcel Therapeutics nets $55.8mm in IPO
22 Apr 2022
Executive Summary
BioXcel Therapeutics Inc. (artificial intelligence (AI) platform to identify neuro and immuno-oncology drugs) netted $55.8mm in its initial public offering of 5.45mm shares at $11 (the low end of its anticipated $11-13 range for 5mm shares).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AI drug development start-up BioXcel Therapeutics nets $55.8mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice